Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Pharmaceutical Technology

MARCH 28, 2023

lower than the previous market day’s close. There is much interest in the industry around RNA-based therapeutics as their utilisation in indications beyond Covid-19 come into focus. Covid-19 vaccine-related revenue is predicted to drop from an estimated $17.1bn in 2022 to $5bn in 2023.

Vaccine 276

Vaccine Vaccination Development Clinical Trials 276

Pharmaceutical Technology

NOVEMBER 8, 2022

Additionally, Neurophth will oversee the clinical trials and marketing of gene therapy products developed leveraging the new AAV capsids of Cyagen. Both companies will assess the new AAV vectors’ functional effects in rodent and NHP models.

Gene Therapy 305

Gene Therapy Gene Development Genetics 305

pharmaphorum

JANUARY 19, 2022

The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. Its mission is to introduce and accelerate the adoption of groundbreaking life science research tools to their markets.

RNA 72

RNA Research Life Science Bioinformatics 72

Roots Analysis

AUGUST 17, 2023

Genome sequencing has historically been classified into DNA sequencing and RNA sequencing. There are several RNA sequencing service providers coming in this market. Due to lack of in-house RNA sequencing facilities, many stakeholders are dependent on service provider, leads to rise demand of RNA sequencing services.

RNA 52

RNA DNA Genome Genomics 52

World of DTC Marketing

DECEMBER 29, 2020

Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. It’s estimated that the COVID 19 vaccine market could be worth almost $100 billion. The coronavirus vaccines, however, took less than a year.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

XTalks

APRIL 1, 2025

Through RNA silencing, it targets the expression of antithrombin, a protein that inhibits blood clotting. Qfitlia is the second RNA interference therapy to receive a highly anticipated FDA approval recently. Qfitlia will be entering a small but competitive market. Sanofi is not new to the hemophilia market.

FDA Approval 59

FDA Approval RNA Clinical Trials Clinical Trials 59

BioTech 365

FEBRUARY 3, 2022

RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor Drug Pipeline Market Research Report 2022 – ResearchAndMarkets.com RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor Drug Pipeline Market Research Report 2022 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA-Dependent RNA Polymerase (RdRP (..)

RNA 40

RNA Marketing Research Drugs 40

pharmaphorum

MAY 14, 2021

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. It’s not the first partnership for Biogen in the RNA splicing area.

RNA 60

RNA Licensing Licensing Genetics 60

pharmaphorum

NOVEMBER 1, 2022

14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Date: 8 – 9 February 2023.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

pharmaphorum

OCTOBER 18, 2021

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. Delve into the latest innovations in novel RNA delivery and target specificity. Engage in the growing advances and development of RNA tools for vaccines and anti-infectives. London, UK.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

XTalks

FEBRUARY 24, 2025

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials 59

Trials RNA Allergies Drugs 59

BioTech 365

OCTOBER 21, 2021

Global RNA Analysis Market Research Report 2021 – ResearchAndMarkets.com Global RNA Analysis Market Research Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global RNA Analysis Market 2021-2026” report has been added to ResearchAndMarkets.com’s offering.

RNA 40

RNA Marketing Research 40

BioTech 365

SEPTEMBER 13, 2021

Global RNA Analysis/Transcriptomics … Continue reading →

RNA 40

RNA Marketing 40

XTalks

NOVEMBER 15, 2024

XTALKS WEBINAR: Solutions for Vaccine Innovation and Gene Therapy: Unlocking the Power of RNA Live and On-Demand: Tuesday, December 17, 2024 , at 9am EST (3pm CET / EU-Central) Register for this free webinar to explore how next-generation RNA technologies can provide effective solutions for vaccine innovation and gene therapy.

Vaccine 105

Vaccine Vaccination Gene Therapy RNA 105

Pharmaceutical Technology

AUGUST 21, 2022

An RNA-dependent RNA polymerase (RdRp) inhibitor, ASC10 is an oral double prodrug. In March this year, the company filed applications seeking marketing authorisation for ritonavir in eight European countries, namely the Netherlands, Portugal, Spain, Denmark, Belgium, Poland, Sweden and Italy.

In-Vivo 162

In-Vivo RNA Clinical Development Drugs 162

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. This led to a period of time when six mRNA vaccines, three from Pfizer/BioNTech and three from Moderna, were available in the US market. There are currently 32 vaccines in Phase III late-stage development across the seven major markets (7MM).

Vaccine 52

Vaccine Vaccination RNA Development 52

Pharmaceutical Technology

APRIL 3, 2023

In the dynamically growing market for cell and gene therapies, viral vectors are needed to deliver the genes of interest into cells. GlobalData, the parent company of Pharmaceutical Technology, outlines a rise in gene therapy trials in 2023, in line with the growing market Fáber describes.

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

BioTech 365

AUGUST 28, 2020

DUBLIN–(BUSINESS WIRE)–The “RNA-interference (RNAi) Market – Growth, Trends, and Forecast (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering. The RNA-interference (RNAi) market is expected to witness a CAGR of 10.12% during the forecast period.

RNA 40

RNA Marketing 40

BioTech 365

JANUARY 14, 2022

RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Analysis / Transcriptomics – Global (..)

RNA 40

RNA Marketing 40

pharmaphorum

JANUARY 6, 2022

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.

RNA 52

RNA Licensing Licensing Development 52

BioTech 365

FEBRUARY 3, 2022

Viral RNA Polymerase Inhibitor Drug Pipeline Market Research Report 2022: Therapeutics Scenario and Growth Prospects Across Viral RNA Polymerase Inhibitor Development – ResearchAndMarkets.com Viral RNA Polymerase Inhibitor Drug Pipeline Market Research Report 2022: Therapeutics Scenario and Growth Prospects Across Viral … Continue reading (..)

RNA 40

RNA Marketing Development Research 40

BioTech 365

JUNE 25, 2021

Africa DNA-RNA Sample Preparation Market Report 2021: Prospects, Trends Analysis, Market Size and Forecasts up to 2025 – ResearchAndMarkets.com Africa DNA-RNA Sample Preparation Market Report 2021: Prospects, Trends Analysis, Market Size and Forecasts up to 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The … Continue (..)

RNA 40

RNA DNA Marketing 40

Pharma Mirror

FEBRUARY 2, 2022

Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome.

RNA 130

RNA Manufacturing Clinical Trials Clinical Trials 130

BioPharma Reporter

SEPTEMBER 7, 2021

Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

Development 131

Development RNA Medicine Regulation 131

BioTech 365

SEPTEMBER 13, 2021

Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth (..)

RNA 40

RNA Marketing 40

Pharmaceutical Technology

JULY 28, 2022

Cobitolimod, an agent being developed for patients with moderate to severely active UC, has both a novel MOA and a route of administration that is unique among marketed agents. Obefazimod is a micro-RNA-124 upregulator that ultimately inhibits the production of inflammatory mediators associated with UC.

Trials 246

Trials Marketing RNA Development 246

Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. RNA has the potential to underpin breakthrough treatments for a wide variety of diseases, including many cancers, and transform medicine as we know it.

Bioassay 130

Bioassay RNA Development Drugs 130

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The market for mRNA-based vaccines and therapeutics is projected to grow from $46.7 RNA technology is not new nor has its potential been surprising.

Life Science 98

Life Science RNA Vaccine Vaccination 98

Pharmaceutical Technology

DECEMBER 11, 2022

The first subject was dosed in the trial, which is designed to evaluate the safety, tolerability and immunogenicity of a nucleoside-modified RNA-based combination vaccine approach. In November, the companies announced plans for a Phase I clinical trial of the combined vaccine candidate in healthy adult subjects.

Vaccine 289

Vaccine Vaccination Gene Therapy Gene 289

pharmaphorum

APRIL 30, 2021

With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce compounds that might alter the course of a disease. The post Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast appeared first on.

RNA 52

RNA Vaccine Vaccination Drugs 52

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccine 52

BioTech 365

OCTOBER 7, 2021

Global DNA & RNA Banking Services (Storage Service, Quality Control Service) Market Trends, Analysis & Forecasts Report 2021-2028 – ResearchAndMarkets.com Global DNA & RNA Banking Services (Storage Service, Quality Control Service) Market Trends, Analysis & Forecasts Report 2021-2028 – ResearchAndMarkets.com … (..)

RNA 40

RNA DNA Marketing 40

BioTech 365

SEPTEMBER 13, 2021

United States RNA Analysis/Transcriptomics Market Research Report 2021 – Forecast to 2026 – Cumulative Impact of COVID-19 – ResearchAndMarkets.com United States RNA Analysis/Transcriptomics Market Research Report 2021 – Forecast to 2026 – Cumulative Impact of COVID-19 – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

RNA 40

RNA Marketing Research 40

Pharmaceutical Technology

OCTOBER 5, 2022

miRecule and Sanofi have entered a strategic partnership and exclusive licence agreement for the development and commercialisation of an antibody-RNA conjugate (ARC) to treat facioscapulohumeral muscular dystrophy (FSHD). The anti-DUX4 RNA therapy was discovered using the DREAmiR platform of miRecule.

Development 130

Development RNA Gene Therapy Sales 130

BioPharma Reporter

MARCH 9, 2023

Arranta Bio, a Recipharm company, is doubling capacity at its Massachusetts facility for process development services supporting RNA therapeutics.

RNA 52

RNA Development Regulation Marketing 52

BioPharma Reporter

APRIL 30, 2024

A recent study finds RNA deals are âdominatedâ by oligonucleotides and mRNA vaccines in APAC

RNA 52

RNA Vaccine Vaccination Regulation 52